Research programme: cell therapies - ViaCell
Latest Information Update: 06 Apr 2011
At a glance
- Originator ViaCell
- Developer Amgen; ViaCell
- Class Cell therapies
- Mechanism of Action Cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Heart failure; Muscular dystrophies; Stroke